SPOTLIGHT -
Current Use of Antipsychotic Medications: A Conversation With Phillip R. Muskin, MD
Phillip R. Muskin, MD, discusses the complexities of prescribing antipsychotics, emphasizing patient collaboration and the importance of evaluating treatment strategies.
Developing a Small Molecule With Lithium's Benefits, But Not its Baggage: A Conversation With Jonathan M. Meyer, MD, DLFAPA
Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.
Insulin Is an Antidepressant: A Conversation With Roger McIntyre, MD, FRCPC
Discover how insulin influences mood and cognition, revealing new therapeutic possibilities for depression and bipolar disorder, in this discussion with Roger McIntyre, MD, FRCPC, at the 2025 APA Annual Meeting.
A Shift in the Way We Think About the Biology of Depression: A Conversation With John H. Krystal, MD
Experts discuss groundbreaking insights on ketamine's role in treating depression, highlighting its rapid effects and potential to transform psychopharmacology.
Assessing Adult ADHD: A Conversation With Jeffrey Newcorn, MD
How does adult ADHD differ from pediatric ADHD? Jeffrey Newcorn, MD, shared his expertise at the 2025 APA Annual Meeting.
Use of Plasma Levels of Antipsychotics: A Conversation With Jonathan M. Meyer, MD, DLFAPA
Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.
